PERISCOPE: road towards effective control of pertussis
Dimitri Diavatopoulos
(1)
,
Kingston H.G. Mills
(2)
,
Kent Kester
(3)
,
Beate Kampmann
(4, 5)
,
Marcela Silerova
(6)
,
Ulrich Heininger
(7)
,
Jacques J.M. van Dongen
(8)
,
Robbert van Der Most
(6)
,
Martijn Huijnen
(1)
,
Emilio Siena
(9)
,
Nathalie Mielcarek
(10)
,
Martina Ochs
(11)
,
Philippe Denoël
(6)
,
Guy Berbers
(12)
,
Anne Marie Buisman
(12)
,
Marien I. de Jonge
(1)
,
Craig Fenwick
(13)
,
Andrew Gorringe
(14)
,
Qiushui He
(15)
,
Dominic Kelly
(16)
,
Roger Le Grand
(17)
,
Camille Locht
(10)
,
Francoise Mascart
(18)
,
Jussi Mertsola
(15)
,
Alberto Orfao
(19)
,
Giuseppe Pantaleo
(13)
,
Andrew J Pollard
(16)
,
Andrew Preston
(20)
,
Robert Read
(21)
,
Peter Sebo
(22)
,
Cecile van Els
(12)
,
Branislav Vecerek
(22)
,
Patricia Londoño-Hayes
(11)
,
Ronald de Groot
(1)
1
Radboud University Medical Center [Nijmegen]
2 Trinity College Dublin
3 Discovery Drive - Sanofi Pasteur [Swiftwater, PN, USA]
4 MRC - Medical Research Council Unit The Gambia
5 LSHTM - London School of Hygiene and Tropical Medicine
6 GlaxoSmithKline Vaccines [Rixensart, Belgium]
7 Unibas - Université de Bâle = University of Basel = Basel Universität
8 LUMC - Leiden University Medical Center
9 GSK - GlaxoSmithKline [Siena, Italy]
10 CIIL - Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204
11 Sanofi Pasteur [Marcy-l'Étoile, France]
12 RIVM - National Institute for Public Health and the Environment [Bilthoven]
13 UNIL - Université de Lausanne = University of Lausanne
14 Public Health England [London]
15 University of Turku
16 University of Oxford
17 IMVA - U1184 - Immunologie des Maladies Virales et Autoimmunes
18 ULB - Université libre de Bruxelles
19 Universidad de Salamanca
20 University of Bath [Bath]
21 University Hospital Southampton NHS Foundation Trust [Southampton, UK]
22 CAS - Czech Academy of Sciences [Prague]
2 Trinity College Dublin
3 Discovery Drive - Sanofi Pasteur [Swiftwater, PN, USA]
4 MRC - Medical Research Council Unit The Gambia
5 LSHTM - London School of Hygiene and Tropical Medicine
6 GlaxoSmithKline Vaccines [Rixensart, Belgium]
7 Unibas - Université de Bâle = University of Basel = Basel Universität
8 LUMC - Leiden University Medical Center
9 GSK - GlaxoSmithKline [Siena, Italy]
10 CIIL - Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204
11 Sanofi Pasteur [Marcy-l'Étoile, France]
12 RIVM - National Institute for Public Health and the Environment [Bilthoven]
13 UNIL - Université de Lausanne = University of Lausanne
14 Public Health England [London]
15 University of Turku
16 University of Oxford
17 IMVA - U1184 - Immunologie des Maladies Virales et Autoimmunes
18 ULB - Université libre de Bruxelles
19 Universidad de Salamanca
20 University of Bath [Bath]
21 University Hospital Southampton NHS Foundation Trust [Southampton, UK]
22 CAS - Czech Academy of Sciences [Prague]
Nathalie Mielcarek
- Fonction : Auteur
- PersonId : 735932
- IdHAL : nathalie-mielcarek
- ORCID : 0000-0002-5968-9442
- IdRef : 104746904
Roger Le Grand
- Fonction : Auteur
- PersonId : 755797
- ORCID : 0000-0002-4928-4484
- IdRef : 077774833
Giuseppe Pantaleo
- Fonction : Auteur
- PersonId : 758701
- ORCID : 0000-0003-3651-2721
Résumé
The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...